TD Cowen Issues Pessimistic Forecast for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target decreased by equities research analysts at TD Cowen from $145.00 to $140.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. TD Cowen’s price objective would suggest a potential upside of 48.93% from the stock’s previous close.

MIRM has been the subject of several other reports. Evercore reissued an “outperform” rating and set a $138.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. CLSA set a $146.00 target price on Mirum Pharmaceuticals in a research report on Monday, June 15th. Citigroup reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Thursday. Raymond James Financial restated a “strong-buy” rating and set a $165.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. Finally, HC Wainwright dropped their price target on shares of Mirum Pharmaceuticals from $185.00 to $140.00 and set a “buy” rating for the company in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $137.33.

Mirum Pharmaceuticals Price Performance

Mirum Pharmaceuticals stock traded down $11.78 during midday trading on Thursday, reaching $94.01. 2,358,378 shares of the company were exchanged, compared to its average volume of 894,935. The company has a market capitalization of $5.73 billion, a price-to-earnings ratio of -6.93 and a beta of 0.52. Mirum Pharmaceuticals has a 1 year low of $54.74 and a 1 year high of $130.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 1.99 and a current ratio of 2.09. The firm’s 50-day simple moving average is $110.46 and its 200-day simple moving average is $101.77.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The firm had revenue of $176.24 million for the quarter, compared to analysts’ expectations of $166.33 million. During the same period in the previous year, the company posted ($0.12) EPS. The business’s quarterly revenue was up 37.9% on a year-over-year basis. On average, analysts anticipate that Mirum Pharmaceuticals will post -2.01 EPS for the current year.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $122.25, for a total value of $611,250.00. Following the sale, the chief financial officer owned 42,181 shares in the company, valued at approximately $5,156,627.25. This trade represents a 10.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 2,721 shares of Mirum Pharmaceuticals stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $120.00, for a total value of $326,520.00. Following the sale, the senior vice president directly owned 3,114 shares in the company, valued at $373,680. The trade was a 46.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 67,155 shares of company stock worth $7,185,662 in the last three months. 8.32% of the stock is owned by insiders.

Institutional Trading of Mirum Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Cullen Frost Bankers Inc. purchased a new stake in shares of Mirum Pharmaceuticals in the 4th quarter valued at approximately $30,000. Eurizon Capital SGR S.p.A. acquired a new stake in Mirum Pharmaceuticals in the 4th quarter worth approximately $32,000. CIBC Private Wealth Group LLC acquired a new position in shares of Mirum Pharmaceuticals during the fourth quarter worth approximately $32,000. State of Wyoming acquired a new position in Mirum Pharmaceuticals in the 2nd quarter valued at approximately $52,000. Finally, Quantbot Technologies LP bought a new stake in Mirum Pharmaceuticals in the 3rd quarter valued at $33,000.

Mirum Pharmaceuticals News Roundup

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Mirum reported second-quarter revenue of $176.24 million, above the $166.33 million analyst consensus, with sales up 37.9% year over year. Growth was driven by Livmarli and the company’s bile-acid products. Mirum’s Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
• Positive Sentiment: The company raised its 2026 revenue outlook to $680 million-$700 million, above the roughly $675 million consensus estimate, supporting the long-term commercial growth story.
• Positive Sentiment: Despite lowering their targets, Citizens JMP maintained a “market outperform” rating at $137, while HC Wainwright retained a “buy” rating with a $140 target—both implying substantial upside based on the referenced price levels. Citizens Says FDA’s Unexpected Phase 3 Request Clouds Mirum’s Near-Term Outlook
• Neutral Sentiment: Analysts cut price targets from $146 to $137 and from $185 to $140, signaling reduced near-term expectations but continued confidence in Mirum’s longer-term prospects.
• Negative Sentiment: The FDA’s unexpected Phase 3 request introduces potential development delays, higher costs and greater uncertainty around Mirum’s pipeline, prompting the sharp investor reaction.
• Negative Sentiment: Mirum’s quarterly loss was wider than expected—reported EPS was approximately $1.06 below zero versus a consensus loss of $0.74—and the loss expanded from the prior year’s $0.12 per-share loss. Mirum Pharmaceuticals Quarterly Earnings Report
• Negative Sentiment: Senior Vice President Jolanda Howe sold 1,840 shares worth approximately $193,734 under a pre-arranged Rule 10b5-1 plan. While scheduled selling reduces its signaling value, the transaction cut her direct holdings by about 59%.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.